Loading…
← CockpitCompetitor Analysis › 002252.SZ Shanghai RAAS Blood Products Co., Ltd. Class AOpen in the cockpit ↗

Shanghai RAAS Blood Products Co., Ltd. Class A002252.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese plasma-products company that collects blood plasma and makes albumin, immunoglobulin and clotting-factor drugs.

≈ A Chinese CSL Behring/GrifolsMomentum strong 76
Mkt cap
$4.57B
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$32.2M
20-day average traded
Fwd P/E
12.8×
forward earnings
ROIC−WACC
-2.4 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
149 days
16 Apr 2027
Close · CNYCN¥4.65
1D-0.4%
1W-3.7%
1M-4.7%
3M-7.4%
6M-14.5%
YTD-26.7%
1Y-31.1%
ATR %2.3%
52w lowhigh33.3% off high

What Shanghai RAAS Blood Products does

Chinese plasma-products company that collects blood plasma and makes albumin, immunoglobulin and clotting-factor drugs.

Sells drugs made from donated plasma, so the amount it can collect at its own stations, and therefore produce, limits growth more than demand does. Albumin and immunoglobulin make up most of sales, supplied to hospitals mostly through distributors. Spain's Grifols was long a major shareholder.

In one line: A Chinese CSL Behring/Grifols.

Products and services

  • Human albumin
  • Intravenous immunoglobulin (IVIG)
  • Coagulation factor products

Customers

  • Hospitals
  • Distributors

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Plasma-derived products

What could go right

  • Rising plasma collection volumes
  • Import substitution for plasma products

What could go wrong

  • Plasma-collection license/regulatory limits
  • Centralized-procurement pricing pressure

Moat: narrow (regulatory licence, scale, installed base). Plasma-collection licenses are capped and hard to obtain, giving incumbents a scale/supply moat.

Headquarters: Shanghai, China · Employees: 4,045

Named competitors

Shanghai RAAS Blood Products at a glance

Size Shanghai RAAS Blood Products (002252.SZ) is a China Health Care company (Biotechnology) with a market value of $4.57B, the 522nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.65 on 18 Nov 2026.

Performance Over six months the shares fell 14.5%, against +2.0% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue fell 22.0% over the last twelve months (peer median +8.3%); the operating margin is 16.7% (peer median -15.6%).

Valuation It trades at 12.8× forward earnings against a peer median of 33.1× (2nd cheapest of 8).

Capital Return on invested capital runs 2.4 points below its cost of capital (5.0% WACC).

Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 101002252.SZ 86
Six months, rebased to 100: Shanghai RAAS Blood Products against the median of its 20 peers (local-currency closes).

Shanghai RAAS Blood Products financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.20BCN¥7.33BCN¥8.15BCN¥7.94BCN¥6.55B
Revenue growth—-10%+3%+21%—
Gross profitCN¥2.38BCN¥2.66BCN¥3.24BCN¥3.19BCN¥2.83B
EBITDAn/aCN¥1.82BCN¥2.31BCN¥2.48BCN¥2.18B
Net incomeCN¥1.09BCN¥1.58BCN¥2.19BCN¥1.78BCN¥1.88B
Free cash flow-CN¥1.08B-CN¥484M-CN¥591MCN¥1.90BCN¥1.54B
Capital expenditureCN¥476MCN¥379MCN¥407MCN¥451MCN¥226M
Total debtCN¥4.24BCN¥3.95BCN¥93.9MCN¥115MCN¥3.82M

Quarterly statements and history in the cockpit →

Shanghai RAAS Blood Products competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%ADPTEWTX000661DNTH3347COGT15306033926696300122CRSPANTHEMCAITNGX6127RLAYABCLSRRKIRON600161002252.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai RAAS Blood Products is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×60×80×00066133471530ANTHEMCAI6127600161002252.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai RAAS Blood Products is the large dot.

Shanghai RAAS Blood Products competitors and peer comparison

Head to head with its named competitors (002252.SZ vs 002007.SZ vs 600161.SS vs CSL.AX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shanghai RAAS Blood Products 002252.SZ$4.57B-15%-22%17%12.8×n/a
Hualan Biological Engineering 002007.SZ$3.20B-17%-11%17%26.7×15.8%
Beijing Tiantan Biological Products 600161.SS$3.47B-13%-13%21%33.1×2.2%
CSL CSL.AX$63.7B+102%-2%26%21.5×6.8%
Grifols GRF.MC$7.48B+19%+1%16%13.1×7.1%

How Shanghai RAAS Blood Products compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai RAAS Blood Products against its 20 peers (data as of 18 Nov 2026)
Measure002252.SZPeer medianRank in peer set
1-month return-4.7%-4.9%11th highest of 21
6-month return-14.5%+2.0%5th lowest of 21
Distance from 52-week high-33.3%-32.3%10th lowest of 21
Revenue growth (TTM)-22.0%+8.3%4th lowest of 16
Operating margin16.7%-15.6%4th highest of 16
Forward P/E12.8×33.1×2nd cheapest of 8
ROIC minus cost of capital-2.4 pp-11.2 pp5th highest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%12.8×n/an/a
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%n/an/an/a
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%30.3×32.4%+7.1%
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%n/an/an/a
Hangzhou Tigermed Consulting 3347.HKHong Kong$4.75B0%+22%10%59.8×25.4%+15.6%
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%12.0×n/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%n/an/an/a
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%n/a-6.5%-10.0%
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%n/an/an/a
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%64.3×36.9%+26.2%
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%79.4×18.2%+61.5%
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
JOINN Laboratories (China) 6127.HKHong Kong$3.70B+6%+17%-4%14.4×n/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%n/an/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%n/an/an/a
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%n/an/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%33.1×2.2%+12.5%

Questions

Who are Shanghai RAAS Blood Products's main competitors?
Named competitors: Hualan Biological Engineering (002007.SZ), Beijing Tiantan Biological Products (600161.SS), CSL Behring (CSL.AX), Grifols (GRF.MC). The cockpit's measured peer set (industry) also includes Adaptive Biotechnologies (ADPT), Edgewise Therapeutics (EWTX), Changchun High-Tech Industry (Group) (000661.SZ), Dianthus Therapeutics (DNTH), Hangzhou Tigermed Consulting (3347.HK), Cogent Biosciences (COGT).
Is Shanghai RAAS Blood Products expensive compared with its peers?
On forward p/e it trades at 12.8× against a peer median of 33.1×, 2nd cheapest of 8 in its peer set.
How has Shanghai RAAS Blood Products stock performed?
Over six months to 18 Nov 2026 the shares returned -14.5% against +2.0% for the median peer; over one year -31.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.